G0902173/MRC_/Medical Research Council/United Kingdom[Grants and Funding] - Search Results

Year	Number of Results
2005	1
2007	5
2008	2
2009	4
2010	5
2011	1
2012	2
2013	2
2014	2
2015	5
2016	2
2024	0

1

Biomarkers of angiogenesis and their role in the development of VEGF inhibitors.

Murukesh N, Dive C, Jayson GC. Murukesh N, et al. Br J Cancer. 2010 Jan 5;102(1):8-18. doi: 10.1038/sj.bjc.6605483. Epub 2009 Dec 15. Br J Cancer. 2010. PMID: 20010945 Free PMC article. Review.

2

Antiangiogenic drugs in ovarian cancer.

Kumaran GC, Jayson GC, Clamp AR. Kumaran GC, et al. Br J Cancer. 2009 Jan 13;100(1):1-7. doi: 10.1038/sj.bjc.6604767. Epub 2008 Nov 11. Br J Cancer. 2009. PMID: 19002176 Free PMC article. Review.

3

Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives.

O'Connor JP, Jackson A, Asselin MC, Buckley DL, Parker GJ, Jayson GC. O'Connor JP, et al. Lancet Oncol. 2008 Aug;9(8):766-76. doi: 10.1016/S1470-2045(08)70196-7. Lancet Oncol. 2008. PMID: 18672212 Review.

4

Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging.

Jackson A, O'Connor JP, Parker GJ, Jayson GC. Jackson A, et al. Clin Cancer Res. 2007 Jun 15;13(12):3449-59. doi: 10.1158/1078-0432.CCR-07-0238. Clin Cancer Res. 2007. PMID: 17575207 Free article. Review.

5

Lymphatic vessel density, microvessel density and lymphangiogenic growth factor expression in colorectal cancer.

Duff SE, Jeziorska M, Kumar S, Haboubi N, Sherlock D, O'Dwyer ST, Jayson GC. Duff SE, et al. Colorectal Dis. 2007 Nov;9(9):793-800. doi: 10.1111/j.1463-1318.2006.01199.x. Colorectal Dis. 2007. PMID: 17931169

6

VEGF inhibitors and advanced ovarian cancer.

Jayson G. Jayson G. Lancet Oncol. 2011 Nov;12(12):1082-3. doi: 10.1016/S1470-2045(11)70269-8. Epub 2011 Oct 10. Lancet Oncol. 2011. PMID: 21992854 No abstract available.

7

Heparin octasaccharides inhibit angiogenesis in vivo.

Hasan J, Shnyder SD, Clamp AR, McGown AT, Bicknell R, Presta M, Bibby M, Double J, Craig S, Leeming D, Stevenson K, Gallagher JT, Jayson GC. Hasan J, et al. Clin Cancer Res. 2005 Nov 15;11(22):8172-9. doi: 10.1158/1078-0432.CCR-05-0452. Clin Cancer Res. 2005. PMID: 16299249

8

Synthesis and scalable conversion of L-iduronamides to heparin-related di- and tetrasaccharides.

Hansen SU, Miller GJ, Baráth M, Broberg KR, Avizienyte E, Helliwell M, Raftery J, Jayson GC, Gardiner JM. Hansen SU, et al. J Org Chem. 2012 Sep 21;77(18):7823-43. doi: 10.1021/jo300722y. Epub 2012 Sep 4. J Org Chem. 2012. PMID: 22900939

9

The development of anti-angiogenic heparan sulfate oligosaccharides.

Jayson GC, Miller GJ, Hansen SU, Barath M, Gardiner JM, Avizienyte E. Jayson GC, et al. Biochem Soc Trans. 2014 Dec;42(6):1596-600. doi: 10.1042/BST20140229. Biochem Soc Trans. 2014. PMID: 25399576

10

Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer.

Cole C, Lau S, Backen A, Clamp A, Rushton G, Dive C, Hodgkinson C, McVey R, Kitchener H, Jayson GC. Cole C, et al. Cancer Biol Ther. 2010 Sep 1;10(5):495-504. doi: 10.4161/cbt.10.5.12585. Epub 2010 Sep 4. Cancer Biol Ther. 2010. PMID: 20595807 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

28 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year